In addition, several clinicopathological and molecular features determine the outcome of patients with gliomas, such as WHO grade, isocitrate dehydrogenase 1/2 (IDH1/2) mutations, 1p/19q co-deletion, MGMT promoter methylation, subtype (Reifenberger et al., 2017; Molinaro et al., 2019). Here, IDH1 is linked to central nervous system cancer.